Aerpio starts dosing in Phase IIb trial of diabetic retinopathy drug

US-based Aerpio Pharmaceuticals has started dosing patients in the Phase IIb (TIME-2b) clinical trial of its product candidate AKB-9778, which could be used to treat patients with non-proliferative diabetic retinopathy.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news